Other: blood drawing only group c (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00987831 (ClinicalTrials.gov) | May 2009 | 30/9/2009 | Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE) | Biomarkers of Lupus Disease: Study of Biomarker Changes Before and After Treatment With Depomedrol and Background Medication Withdrawal in Patients With Mild to Moderate SLE Disease Activity | Systemic Lupus Erythematosus | Other: Group B SLE one blood donation;Other: Blood drawing only Group C;Drug: Group A SLE prospective study | Oklahoma Medical Research Foundation | Pfizer | Completed | 14 Years | 70 Years | All | 158 | Phase 1;Phase 2 | United States |